Alcidion (ASX: ALC) AGM and Q1 FY 2025 Results
There was nothing much to celebrate arising from the Alcidion AGM and Q1 FY 2025 update.
Alcidion (ASX: ALC)
Alcidion Group Ltd (ASX: ALC) is a medical software company specialising in patient flow software for hospitals. Basically, Alcidion’s Miya platform makes it easier for nurses to manage beds in wards, and ensures that the appropriate medico has assessed test results, and taken appropriate action. Alcidion can be seen as an important software partner for public healthcare systems such as Australia’s Medicare, and the United Kingdom’s NHS.
Alcidion (ASX: ALC) FY 2024 Results Were Very Weak, As Expected
The company says FY 2025 will be an improvement.
Alcidion (ASX: ALC) Q4 FY 2024 Update (June 2024 Quarter)
A seasonally strong fourth quarter tops off an incredibly disappointing FY 2024 for hospital workflow software stock Alcidion (ASX: ALC).
Alcidion (ASX: ALC) Rising From The Ashes, Plus Quarterly Update
Was the dumpster fire sufficiently non-toxic to grow something valuable from the ashes?
Alcidion (ASX: ALC) H1 FY 2024 Results
Alcidion (ASX: ALC) would probably be worth more to an acquirer, than as a public company.
Alcidion (ASX: ALC) Q2 FY 2024 Quarterly Results
Yet another disappointing quarterly from Alcidion (ASX: ALC), as much needed contract wins fail to materialise.
Upcoming AGMs In November 2023
Here are some of the small-cap Annual General Meetings coming up this month.
Alcidion’s (ASX: ALC) Weak Quarter And Capital Raising
Alcidion (ASX: ALC) is raising capital due delays in NHS procurement.
Alcidion (ASX: ALC) FY 2023 Results
Alcidion’s CEO Kate Quirke says “we have a very long runway ahead of us” and “at this stage I am confident.”
Alcidion (ASX: ALC) Reports Record Quarterly Cashflow in Q4 FY 2023 Appendix 4C
Alcidion’s cashflow is heading in the right direction but still no word on when to expect statutory profits.
Alcidion (ASX: ALC) Q3 FY 2023 Quarterly Report
NHS strikes are taking a toll on Alcidion’s sales cycle.
Alcidion (ASX: ALC) Reports Strong New Sales, But Weak Cashflow, in Q2 FY 2023
A couple of late payments (now received) contributed to disappointing cashflow for Alcidion, in Q2 FY 2023.
Encouraging Contract Wins For Duratec (ASX: DUR) And Alcidion (ASX: ALC)
Alcidion is an unprofitable healthcare software stock, and Duratec is a low margin contractor. But both companies are winning new contracts.
Laserbond, PWR Holdings, Alcidion, Objective, and Lovisa Results Discussion On Rask Podcast
PWR Holdings results, Objective
results, Alcidion results, Lovisa results and Laserbond results were all strong in FY 2022.
The ASX Med-Tech Stocks I Am Buying Next
These two med-tech stocks are still fairly high risk, but they are approaching the profitability inflection point, and have long term tailwinds supporting the businesses.
Alcidion (ASX: ALC) Q3 FY2022 Quarterly Results
The Alcidion (ASX: ALC) is flat today as the company reports weaker operating cash flow due to acquisition expenses.
Alcidion (ASX: ALC) Recurring Revenue Falls In H1 FY 2022
The drop in recurring revenue means that the company is lower quality than I had previously believed.
Alcidion (ASX:ALC) Acquires Silverlink Software, Raises Capital At 25c Per Share
Alcidion (ASX:ALC) is bolstering its product offering with its acquisition of Silverlink Software. What does it mean for shareholders?
Alcidion (ASX: ALC) Confirms Large Government Contract (After A Weak Quarter)
The Alcidion share price is up around 10% after it confirmed its largest ever contract win, worth at least $23 million.
What Growing ASX Software Stock Should I Buy Today?
Some stocks have high multiples and higher growth rates, others have lower multiples and lower growth rates. Here’s how I decided which one to choose.